Cargando…
Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma
RATIONALE: Glioblastoma multiforme (GBM) is a primary brain tumor with poor prognosis. The U.S. food and drug administration approved the use of the anti-VEGF antibody bevacizumab in recurrent GBM. However, resistance to this treatment is frequent and fails to enhance the overall survival of patient...
Autores principales: | Joshkon, Ahmad, Tabouret, Emeline, Traboulsi, Wael, Bachelier, Richard, Simoncini, Stéphanie, Roffino, Sandrine, Jiguet-Jiglaire, Carine, Badran, Bassam, Guillet, Benjamin, Foucault-Bertaud, Alexandrine, Leroyer, Aurelie S., Dignat-George, Françoise, Chinot, Olivier, Fayyad-Kazan, Hussein, Bardin, Nathalie, Blot-Chabaud, Marcel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590138/ https://www.ncbi.nlm.nih.gov/pubmed/36274147 http://dx.doi.org/10.1186/s40478-022-01451-3 |
Ejemplares similares
-
Role of CD146 (MCAM) in Physiological and Pathological Angiogenesis—Contribution of New Antibodies for Therapy
por: Joshkon, Ahmad, et al.
Publicado: (2020) -
CD146/sCD146 in the Pathogenesis and Monitoring of Angiogenic and Inflammatory Diseases
por: Heim, Xavier, et al.
Publicado: (2020) -
Soluble CD146 as a Potential Target for Preventing Triple Negative Breast Cancer MDA-MB-231 Cell Growth and Dissemination
por: Sharma, Akshita, et al.
Publicado: (2022) -
Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis
por: Bertaud, Alexandrine, et al.
Publicado: (2023) -
A novel anti-CD146 antibody specifically targets cancer cells by internalizing the molecule
por: Nollet, Marie, et al.
Publicado: (2017)